Serum estradiol levels and bone mineral density in postmenopausal women

Main Article Content

Martiem Mawi


Postmenopausal women are at high risk of disease, such as coronary heart disease, stroke, malignancies, dementia and osteoporosis. This is due to decreased levels of estrogen/estradiol, produced mainly in the ovaries, leading to reduced bone mineral density (BMD), which is the gold standard for diagnosis of osteoporosis. The purpose of the present study was to determine the relationship between serum estradiol levels and BMD in postmenopausal women. The study, which was of cross-sectional design, involved 184 postmenopausal women meeting the inclusion criteria, viz. healthy postmenopausal women aged between 47 and 60 years having taken no hormonal medications in the previous 3 years. The subjects were assessed for anthropometric and biochemical characteristics, including BMD and serum estradiol levels. BMD was measured at the lumbar spine, right femoral neck and at the distal radius by the dual-energy X-ray absorptiometry (DXA) instrument. The mean serum estradiol concentration was 7.54 ± 4.65 pg/ml, while in 49.5% of the subjects the estradiol concentration was £ 5 pg/ml. In postmenopausal women with estradiol concentrations of > 5 pg/ml, a significant positive relationship was found between BMD and the T-scores for the femoral neck. Thus the higher the serum estradiol levels, the higher the BMD values for femoral neck region. In conclusion, the results of this study point to estradiol levels as a major factor in determining the BMD values in postmenopausal women.

Article Details

How to Cite
Mawi, M. (2010). Serum estradiol levels and bone mineral density in postmenopausal women. Universa Medicina, 29(2), 90–95.
Review Article


Baziad A. Menopause and andropause. Jakarta: Yayasan Bina Pustaka Sarwono Prawirohardjo; 2003.

Molina PE. Endocrine physiology. New York: The McGraw-Hill companies; 2004.

Sacco SM, Ward WE. Revisiting estrogen: efficacy and safety for postmenopausal bone health. J Osteoporos 2010;2010:1-7.

Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flushes. Mayo Clin Proc 2002;77:1207-18.

Bagur A, Oliveri B, Mautalen C, Beotti M, Mastaglia S, Yankelevich D, et al. Low level of endogenous estradiol protects bone mineral density in young postmenopausal women. Climacteric 2004;7:181-8.

Simpson ER. Aromatization of androgens in women: current concepts and findings. Fertil Steril 2002;77:6-10.

Matsumine H, Hirato K, Yanaihara T, Tamada Y, Yoshida M. Aromatization by skeletal muscle. J Steroid Biochem Mol Biol 2003;84:485-92.

Guthrie JR, Lehert P, Dennerstein L, Burger HG, Ebeling PR, Wark JD. The relative effect of endogenous estradiol and androgens on menopausal bone loss: a longitudinal study. Osteoporos Int 2004;15:881-6.

Larionov AA, Vasyliev DA, Mason JL, Howie AF, Berstein LM, Miller WR. Aromatase in skeletal muscle. J Clin Endocrinol Metab 2002;3: 1327-36.

Nurhonni SA. Osteoporosis and pencegahannya. Maj Kedokt Indon 2000;50:565-8.

Tana L. Pencegahan osteoporosis. Media Litbang Kesehatan 2005;15:50-7.

Sowers MR, Jannausch M, Mc Connell D, Little R, Greendale GA, Filkelstein JS, et al. Hormone predictors of bone mineral density changes during the menopausal transition. J Clin Endocrinol Metab 2006;91:1261-7.

Ninghua L, Pinzhong O, Harmin Z, Dingzhuo Y, Pinru Z. Prevalence rate of osteoporosis in the mid-aged and elderly in selected parts of China. Clind Med J 2002;115:773-5.

World Health Organization. Appropiate body mass index for Asian populations and its implications for policy and intervention strategies. The Lancet 2004;363:157-63.

World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series 843. Geneva: World Health Organization;1994.

van Geel TACM, Geusens PP, Winkens B, Sels JPJE, Dinant GJ. Measures of bioavailable testosterone and estradiol and their relationships with muscle mass, muscle strength and bone mineral density in postmenopausal women: a cross-sectional study. Eur J Endocrinol 2009;160: 681-7.

Riggs BL, Khosla S, Melton LJ III. Sex steroids and the construction and conservation of adult skeleton. Endocr Rev 2002;23:279–302.

Lea CK, Ebrahim H, Tennant S, Flanagan AM. Aromatase cytochrome P450 transcripts are detected in fractured human bone but not in normal skeletal tissue. J Gerontol A Biol Sci Med Sci 2003;3:266-70.

Morton DJ, Connor EB, Silverstein DK, Wingard DL, Schneider DL. Bone mineral density in postmenopausal Caucasian, Filipina, and Hispanic women. Int J Epidemiol 2003;32:150-6.

Miller PD, Hochberg MC, Wehren LE, Ross PD, and Wasnich RD. How useful are measures of BMD and bone turnover? Curr Med Res Opin 2005;21:545.

Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell A. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 2002;87:4470-5.

Zarrabeitia MT, Hernandez JL, Valero C, Ziarrabeitia A, Amado JA, Macias JG, et al. Adiposity, estradiol, and genetic variants of steroid-metabolizing enzymes as determinants of bone mineral density. Eur J Endocrinol 2007; 156:117-22.